Effects of Nonglucose Nutrients on Insulin Secretion and Action in People With Pre-Diabetes
- Gerlies Bock1,
- Chiara Dalla Man2,
- Marco Campioni2,
- Elizabeth Chittilapilly1,
- Rita Basu1,
- Gianna Toffolo2,
- Claudio Cobelli2 and
- Robert Rizza1
- 1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Rochester, Minnesota
- 2Department of Electronics and Informatics, University of Padova, Padova, Italy
- Address correspondence and reprint requests to Robert A. Rizza, MD, Mayo Clinic, 200 1st St. S.W., Rm. 5-194 Joseph, Rochester, MN 55905. E-mail: rizza.robert{at}mayo.edu
Abstract
To determine whether nonglucose nutrient–induced insulin secretion is impaired in pre-diabetes, subjects with impaired or normal fasting glucose were studied after ingesting either a mixed meal containing 75 g glucose or 75 g glucose alone. Despite comparable glucose areas above basal, glucose-induced insulin secretion was higher (P < 0.05) and insulin action lower (P < 0.05) during the meal than the oral glucose tolerance test (OGTT) in all subgroups regardless of whether they had abnormal or normal glucose tolerance (NGT). However, the nutrient-induced δ (meal minus OGTT) in insulin secretion and glucagon concentrations did not differ among groups. Furthermore, the decrease in insulin action after meal ingestion was compensated in all groups by an appropriate increase in insulin secretion resulting in disposition indexes during meals that were equal to or greater than those present during the OGTT. In contrast, disposition indexes were reduced (P < 0.01) during the OGTT in the impaired glucose tolerance groups, indicating that reduced glucose induced insulin secretion. We conclude that, whereas glucose-induced insulin secretion is impaired in people with abnormal glucose tolerance, nonglucose nutrient–induced secretion is intact, suggesting that a glucose-specific defect in the insulin secretory pathway is an early event in the evolution of type 2 diabetes.
- DI, disposition index
- IFG, impaired fasting glucose
- IGT, impaired glucose tolerance
- IGT-D, impaired glucose tolerance/diabetes
- NFG, normal fasting glucose
- NGT, normal glucose tolerance
- OGTT, oral glucose tolerance test
Footnotes
-
R.A.R. is a consultant for Abbott and Symphony Capital, is on the Scientific Advisory Board for Merck and Mankind, holds stock in Diobex, and is both a consultant of and on the Scientific Advisory Boards for Takeda and Eli Lilly.
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted December 18, 2006.
- Received September 8, 2006.
- DIABETES














